MilliporeSigma Develops New CRISPR Technology
The company developed proxy-CRISPR which provides access to previously unreachable areas of the genome.
On May 17, 2017 MilliporeSigma announced that it has developed a new CRISPR genome-editing tool. This new technique, called proxy-CRISPR, provides access to previously unreachable areas of the genome. Most natural CRISPR systems, found in bacteria, cannot work in human cells without significant re-engineering. Proxy-CRISPR increases their usability without the need to re-engineer native CRISPR proteins, the company noted in a press release. According to MilliporeSigma, the company has filed several patent applications on the proxy-CRISPR technology.
MilliporeSigma's research on proxy-CRISPR, Targeted Activation of Diverse CRISPR-Cas Systems for Mammalian Genome Editing via Proximal CRISPR Targeting, was published in the April 7, 2017 edition of Nature Communications. The article explains how to make CRISPR more efficient, flexible, and specific by opening the genome for the cutting of DNA, giving researchers more editing options.
The new technology is an addition to MilliporeSigma's existing CRISPR applications. The company's next suite of genome editing tools for the research community, to be launched later in 2017, will include novel and modified versions of Cas and Cas-like proteins.
Source: MilliporeSigma
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
